Page last updated: 2024-08-23

razoxane and Cardiotoxicity

razoxane has been researched along with Cardiotoxicity in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Armenian, SH; de Baat, EC; Feijen, EAM; Kremer, LCM; Mavinkurve-Groothuis, AMC; Mulder, RL; van Dalen, EC1
Bavlovič Piskáčková, H; Chládek, J; Jansová, H; Jirkovská, A; Karabanovich, G; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Melnikova, I; Roh, J; Šimůnek, T; Štěrba, M; Štěrbová-Kovaříková, P; Váňová, N1
Benjamin, RS; Minotti, G1

Other Studies

3 other study(ies) available for razoxane and Cardiotoxicity

ArticleYear
Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:10

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Humans; Neoplasms; Polyketides; Razoxane

2023
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
    Scientific reports, 2021, 02-24, Volume: 11, Issue:1

    Topics: Animals; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Male; Myocytes, Cardiac; Piperazine; Prodrugs; Rabbits; Razoxane; Topoisomerase II Inhibitors; Water

2021
Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 07-15, Volume: 27, Issue:14

    Topics: Cardiotoxicity; Dexrazoxane; Doxorubicin; Humans; Razoxane; Sarcoma

2021